Trial
NCT03944902
CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Alabama at Birmingham
Collaborators
—
Condition
Ovarian Cancer
Intervention
Cohort 1: Dose Escalation
Why stopped
will not resume. company choosing not to continue with drug. one participant now off study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-21